279 results on '"Rousseau, Annick"'
Search Results
2. Adherence profiles in kidney transplant patients: Causes and consequences
3. Evaluation of Longitudinal Exposure to Tacrolimus as a Risk Factor of Chronic Kidney Disease Occurrence Within the First Year Post-Liver Transplantation
4. Validation of the psychometrics properties of a French quality of life questionnaire among a cohort of renal transplant recipients less than one year
5. Population pharmacokinetics and Bayesian estimation of mycophenolate mofetil in patients with autoimmune hepatitis
6. Pharmacological exposure to ribavirin: A key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment
7. Population Pharmacokinetics And Bayesian Estimation of Mycophenolate Mofetil In Patients With Autoimmune Hepatitis
8. eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance?
9. Ciclosporin Population Pharmacokinetics and Bayesian Estimation in Thoracic Transplant Recipients
10. Population Pharmacokinetic Modelling and Design of a Bayesian Estimator for Therapeutic Drug Monitoring of Tacrolimus in Lung Transplantation
11. Bayesian Estimation of Mycophenolate Mofetil in Lung Transplantation, Using a Population Pharmacokinetic Model Developed in Kidney and Lung Transplant Recipients
12. Population Pharmacokinetics and Bayesian Estimation of Tacrolimus Exposure in Renal Transplant Recipients on a New Once-Daily Formulation
13. Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients
14. Limited Sampling Models and Bayesian Estimation for Mycophenolic Acid Area under the Curve Prediction in Stable Renal Transplant Patients Co-Medicated with Ciclosporin or Sirolimus
15. Sirolimus Population Pharmacokinetic/Pharmacogenetic Analysis and Bayesian Modelling in Kidney Transplant Recipients
16. Patient Characteristics Influencing Ciclosporin Pharmacokinetics and Accurate Bayesian Estimation of Ciclosporin Exposure in Heart, Lung and Kidney Transplant Patients
17. Pharmacokinetic Study of Tacrolimus in Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Patients and Design of Bayesian Estimators Using Limited Sampling Strategies
18. A Double Absorption-Phase Model Adequately Describes Mycophenolic Acid Plasma Profiles in De Novo Renal Transplant Recipients Given Oral Mycophenolate Mofetil
19. Bayesian Estimation of Methotrexate Pharmacokinetic Parameters and Area Under the Curve in Children and Young Adults with Localised Osteosarcoma
20. Maximum A Posteriori Bayesian Estimation of Oral Cyclosporin Pharmacokinetics in Patients with Stable Renal Transplants
21. Adaptive Control Methods for the Dose Individualisation of Anticancer Agents
22. Inhibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK/PD relationships
23. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations – twice daily Prograf® and once daily Advagraf®
24. Post-transplant lymphoproliferative disease (PTLD): Pharmacological, virological and other determinants
25. Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8*2 variant allele
26. Poster Board #-Session: P240-II T-Cell Activation and Proliferation Measurements as Pharmacodynamic Biomarkers of Mycophenolic Acid Exposure.: Abstract# 1220
27. Poster Board #-Session: P119-II Significant Influence of Hematocrit on Tacrolimus Apparent Clearance in Renal Transplant Patients.: Abstract# 1099
28. Poster Board #-Session: P105-I Advagraf® Pharmacokinetics Analysis in Stable Renal Transplant Patients.: Abstract# 762
29. Ribavirin in chronic hepatitis C: past and future
30. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C
31. Modelling Ciclosporin Double-Peak Absorption Profiles in the Early Post-Transplantation Period
32. A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients
33. Tacrolimus Pharmacokinetics and Dose Monitoring After Lung Transplantation for Cystic Fibrosis and Other Conditions
34. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs
35. A Prognostic Tool for Individualized Prediction of Graft Failure Risk within Ten Years after Kidney Transplantation
36. An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies
37. Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin
38. Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer
39. Exposure to mycophenolic acid better predicts immunosuppressive efficacity than exposure to calcineurin inhibitors in renal transplant patients
40. Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation
41. The PROPKD Score
42. Anti-hepatitis C virus drugs and kidney
43. Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients
44. Ciclosporin population pharmacokinetics and Bayesian estimation in thoracic transplant recipients
45. Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up
46. Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele.: Pharmacogenetics of mycophenolate-induced diarrhea
47. eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance?
48. Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients.
49. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
50. Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.